FORMULATION AND CHARACTERIZATION OF LIQUISOLID TABLETS OF VALSARTAN FOR IMPROVEMENT OF DISSOLUTION RATE
Objective: The solubility and dissolution properties of any drug are vital determinants of its oral bioavailability. The objective of this study
is to screening of non-volatile solvent in which drug shows maximum solubility and then formulation of different liquisolid (LS) compacts using
mathematical equations to increase the dissolution rate of drug.
Materials and Methods: Different LS compacts were prepared using a mathematical model for calculating required quantities of powder and
liquid ingredients to produce an acceptably flowable and compressible admixture. Avicel PH 102, aerosil 200 and crospovidone were employed
as a carrier, coating material and disintegrant, respectively. The prepared LS systems were evaluated for their flow behavior and possible drugexcipient
interactions by infrared (IR) spectra analysis and X-ray diffraction (XRD). Morphological changes in the final formulation were investigated
by scanning electron microscopy (SEM), liquisolid compacts were prepared and evaluated for their tableting properties.
Results: Valsartan shows maximum solubility in propylene glycol a non-volatile solvent. The IR studies ruled out any significant interaction between
the drug and excipients. The XRD analysis confirmed formation of a solid solution inside the compact matrix. SEM indicates that the drug was totally
solubilized in the LS system. The tableting properties of the LS compacts were within the acceptable limits. The release rates of LS compacts were
markedly higher compared with directly compressed tablets due to increasing wetting properties and surface area of the drug.
Conclusion: This study shows that the LS technique is a promising alternative tool for improvement of the dissolution rate of biopharmaceutical
classification system Class II drug.
Keywords: Dissolution rate, Liquisolid compact, Valsartan, Non-volatile solvents, Liquid load factor
Daravath B, Tadikonda R. Formulation and evaluation of meclizine
hydrochloride fast dissolving tablets using solid dispersion method.
Asian J Pharm Clin Res 2014;2:98-102.
Yalkowsky SH, Rubino JT. Solubilization by cosolvents I:
Organic solutes in propylene glycol-water mixtures. J Pharm Sci
Sugawara M, Kadomura S, He X, Takekuma Y, Kohri N, Miyazaki K.
The use of an in vitro dissolution and absorption system to evaluate
oral absorption of two weak bases in pH-independent controlled-release
formulations. Eur J Pharm Sci 2005;26(1):1-8.
Youn YS, Jung JY, Oh SH, Yoo SD, Lee KC. Improved intestinal
delivery of salmon calcitonin by Lys18-amine specific PEGylation:
Stability, permeability, pharmacokinetic behavior and in vivo
hypocalcemic efficacy. J Control Release 2006;114(3):334-42.
Spireas S, Sadu S, Grover R. In vitro release evaluation of hydrocortisone
liquisolid tablets. J Pharm Sci 1998;87(7):867-72.
Spireas S, Wang T, Grover R. Effect of powder substrate on the
dissolution properties of methyclothiazide liquisolid compacts. Drug
Dev Ind Pharm 1999;25(2):163-8.
Nokhodchi A, Javadzadeh Y, Siahi-Shadbad MR, Barzegar-Jalali M.
The effect of type and concentration of vehicles on the dissolution
rate of a poorly soluble drug (indomethacin) from liquisolid compacts.
J Pharm Pharm Sci 2005;8(1):18-25.
Javadzadeh Y, Siahi-Shadbad MR, Barzegar-Jalali M, Nokhodchi A.
Enhancement of dissolution rate of piroxicam using liquisolid
compacts. Farmaco 2005;60(4):361-5.
Spireas S, Sadu S. Enhancement of prednisolone dissolution properties
using liquisolid compacts. Int J Pharm 1998;166:177-88.
Leidig M, Bambauer R, Kirchertz EJ, SzabÃ£ T, Handrock R, Leinung D,
et al. Efficacy, safety and tolerability of valsartan 80 mg compared to
irbesartan 150 mg in hypertensive patients on long-term hemodialysis
(VALID study). Clin Nephrol 2008;69(6):425-32.
BaumhÃ¤kel M, MÃ¼ller U. Valsartan improves symptoms and quality
of life in patients with chronic heart failure. MMW Fortschr Med
Flynn JT, Meyers KE, Neto JP, de Paula Meneses R, Zurowska A,
Bagga A, et al. Efficacy and safety of the Angiotensin receptor blocker
valsartan in children with hypertension aged 1 to 5 years. Hypertension
Kshirsagar SJ, Bhalekar MR, Madgulkar AR, Sable PN, Gupta SR.
Dissolution improvement of poorly water soluble drug valsartan
and improving flow properties of solid dispersion. Lat Am J Pharm
Goodman LS, Gilman A. The Pharmacological Basis of Therapeutics.
th ed. New-York: McGraw Hill Medical Publishing Division;2001.
Srivastava V, Mishra G. Dissolution enhancement of a poorly soluble
model drugs using different formulation approaches for immediate
release solid dosage form. Asian J Pharm Clin Res 2014;7(1):63-6.
Gubbi S, Ravindra J. Formulation and characterisation of atorvastatin
calcium liquisolid compacts. Asian J Pharm 2010;5(2):50-60.
Fahmy RH, Kassem MA. Enhancement of famotidine dissolution rate
through liquisolid tablets formulation: In vitro and in vivo evaluation.
Eur J Pharm Biopharm 2008;69(3):993-1003.
Tayel SA, Soliman II, Louis D. Improvement of dissolution properties
of Carbamazepine through application of the liquisolid tablet technique.
Eur J Pharm Biopharm 2008;69(1):342-7.
Banker GS, Anderson NR. Tablets. In: Lachman L, Lieberman HA,
editors. The Theory and Practice of Industrial Pharmacy. New Delhi:
CBS Publishers;2009. p. 293-345.
Bi YX, Sunada H, Yonezawa Y, Danjo K. Evaluation of rapidly
disintegrating tablets prepared by a direct compression method. Drug
Dev Ind Pharm 1999;25(5):571-81.
Zhao N, Augsburger LL. Functionality comparison of 3 classes of
superdisintegrants in promoting aspirin tablet disintegration and
dissolution. AAPS Pharm Sci Tech 2005;6(4):E634-40.
Venkatesh GS, Averineni R, Usha Y, Armugam K. Enhanced dissolution
and bioavailability of gliclazide using solid dispersion techniques. Int J
Drug Deliv 2010;2:49-57.
How to Cite
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.